RTP Mobile Logo
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Ovarian Cancer (Webinar Video Proceedings)
Released May 2022

Featuring perspectives from Ms Jennifer Filipi, Dr Kathleen Moore, Dr Krishnansu Tewari and Ms Deborah Wright. Published May 24, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with ovarian cancer.


    • Understand the importance of genetic testing for women with newly diagnosed ovarian cancer (OC), and counsel patients regarding the clinical relevance of related testing results.
    • Appreciate published research findings with the use of PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and use this information to explain personalized treatment recommendations to patients.
    • Evaluate available clinical trial results with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC.
    • Recognize the rationale for targeting folate receptor alpha in OC, and consider emerging research findings with and the potential role of novel agents attempting to exploit this biomarker for patients with advanced disease.
    • Assess the toxicities associated with PARP inhibitors and other novel agents used for OC, and offer patients supportive management strategies to minimize and ameliorate these side effects.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for patients with OC, and counsel appropriate individuals about availability and participation.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    This educational activity for 1.75 contact hours is provided by RTP during the period of May 2022 through May 2023.

    This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2022/Ovarian/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2022Ovarian/NCPD.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Jennifer Filipi, MSN, NP
    Department of Gynecologic Oncology
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Kathleen N Moore, MD, MS
    Virginia Kerley Cade Chair in Developmental Therapeutics
    Associate Director for Clinical Research
    Director, Early Phase Drug Development
    Stephenson Cancer Center at the University of Oklahoma HSC
    Professor, Section of Gynecologic Oncology
    Associate Program Director, Gynecologic Oncology Fellowship
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, IMXmed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Lilly, Merck, PTC Therapeutics; Data and Safety Monitoring Board/Committee: SQZ Biotech.

    Krishnansu S Tewari, MD
    Professor and Division Director
    Division of Gynecologic Oncology
    University of California, Irvine
    Irvine, California

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Contracted Research (to Institution): AbbVie Inc, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck.

    Deborah Wright, MSN, APRN, AGCNS-BC
    Clinical Nurse Specialist
    TSET Phase I Program
    Lead Advanced Practice Provider
    Clinical Trials Office
    Stephenson Cancer Center
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Novocure Inc.

    Release date: May 2022
    Expiration date: May 2023

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):